<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04170634</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL17_0642</org_study_id>
    <nct_id>NCT04170634</nct_id>
  </id_info>
  <brief_title>Tumoral Bone Strength Assessment by Numerical Simulation Using Quantitative CT : the MEKANOS Study</brief_title>
  <acronym>MEKANOS</acronym>
  <official_title>Tumoral Bone Strength Assessment by Numerical Simulation Using Quantitative CT (Computed Tomography) : the MEKANOS Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Osteolytic bone metastases and myeloma bone lesions are responsible of long bone and
      vertebral fractures leading to restricted mobility, surgery and medullar compression that
      severely alter quality of life and that have a huge medico-economic impact. It has been
      estimated that 50% of the patients with bone metastasis will encounter bone complications. In
      the recent years, Bone Oncology Multidisciplinary Meetings have been developed to optimize
      bone metastases management for each patient in harmony with oncology program.

      The assessment of the fracture risk of bone metastasis remains fairly empirical and is based
      on simple radiography. The Mirel's score for long bones is focused on the extent of cortical
      defect caused by bone metastasis to identify high-risk patients at risk of fracture during
      surgery. It is old, little used in routine and lacks sensitivity and specificity. The SINS
      (Spinal Instability Neoplastic Score) score is the reference for vertebrae. Today, most
      patients with fracture-risk bone metastasis benefit from a lesion-centered CT scan to better
      characterize its extent and position but the interpretation remains qualitative. Metastases
      are considered as an air cavity and the mechanical properties of the tumor are not evaluated.
      However, many other parameters from the CTscan are available such as cortical or trabecular
      compartment densitometry, cortical thickness, tumor volume, and position of lysis in the
      bone.

      Based on experience acquired by the service in the evaluation of bone mechanical strength on
      benign bones, the investigator aim at integrating in the numerical simulation the mechanical
      properties of both bone and tumor, in order to evaluate the mechanical strength of the
      pathological bone using a numerical simulation model (finite element analysis-FEA).

      MEKANOS will enroll patients with bone metastases of breast, lung, kidney, thyroid or bladder
      cancer and myeloma lesions affecting the vertebrae or the upper end of the femur.

      The resistance obtained will be compared to that of an intact bone. The best predictive
      parameters of mechanical strength (position of lysis, tumor nature, and bone architecture)
      will be then determined. Finally, the added value of this technique in relation to historical
      fragility scores (Mirel's and SINS scores) will be assessed.

      The ultimate goal is to provide tools to assess fracture risk and improve the preventive
      management of bone metastases in harmony with the referring oncologist
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 28, 2019</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of mechanical strength of tumor proximal femur or tumor vertebrae obtained by numerical simulation using the finite element analysis (FEA) method.</measure>
    <time_frame>24 months</time_frame>
    <description>Measurement of mechanical strength (expressed in Newton : N), monopodal support at the upper end of the femur and uniaxial compression on the vertebrae, obtained by numerical simulation using the finite element analysis (FEA) method.
As an indication, the average resistance of a femur of an elderly patient in monopod support is on average 9000 N and that of the L3 vertebra in uniaxial compression is on average 2700 N.
Comparative values will also be obtained on the healthy contralateral femur and an adjacent healthy vertebra of each patient</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Metastases to Bone</condition>
  <condition>Metastatic Breast Cancer</condition>
  <condition>Metastatic NSCLC</condition>
  <arm_group>
    <arm_group_label>Patients with bone metastases at risk of fracture</arm_group_label>
    <description>Adult patients with tumor osteolytic bone lesions located in proximal femur and/or vertebrae secondary to a myeloma or a breast, lung (NSCL: Non-Small Cell Lung), bladder, thyroid or kidney cancer. The target vertebrae or femur has to be naïve of localized treatment (interventional radiology - cementoplasty, cryotherapy, radiofrequency…). Previous exposure to systemic oncological treatments (chemotherapy, targeted therapy, immunotherapy…) and bone treatments are allowed if administered for less than 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Evaluation of the fracture risk using data from routine qCT (quantitative Computed Tomography) scan and numerical simulation</intervention_name>
    <description>Assessment of the mechanical tumor bone strength by numerical simulation using qCT routine imagery of proximal femur (applying a monopodal standing load) and vertebrae (applying a uniaxial compression load).</description>
    <arm_group_label>Patients with bone metastases at risk of fracture</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood collection: 12 mL of blood (4 mL for plasma and 8 mL for serum isolation) will be
      collected at the baseline, concomitantly to routine blood analysis. Plasma and serum will be
      stored at -80°C for further analysis on bone markers (CTX: C-Terminal Telopeptide, DKK1:
      Dickkopf-1, ALP: Alkaline Phosphatase and P1NP: Procollagen I N-Terminal Propeptide).

      Ancillary study: small femur cylinders from fresh tumor samples will be collected during
      standard care procedures and analyzed in order to characterize the viscoelastic properties of
      the tumors.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with predominantly osteolytic tumor involvement related either to myeloma or
        bone metastases of lung, breast, bladder, thyroid or kidney cancer.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients (&gt; 18 years of age).

          -  Patients who do not object to participating in the study. For patients participating
             to the biological collection: signature of the written informed consent..

          -  Patients with secondary tumor lesion(s) of mammary or pulmonary non-small cell, renal,
             bladder, thyroid or myeloma bone origin.

          -  Existence of a CT scan focused on the target lesion (or which will be performed as
             part of the care), performed within a time window of 30 days before and 20 days after
             inclusion, as part of the patient's usual bone management.

          -  Target location: upper end of the femur (1/3 proximal) and/or vertebrae.

          -  Size of target lesion: either diffuse permeative or &gt; 15 mm in size.

          -  Exposure to systemic bone therapy for 3 months or less (daily clodronate or denosumab,
             zoledronic acid, monthly pamidronate) is allowed

          -  Patients who received previous systemic oncological treatments (chemotherapy, targeted
             therapy, immunotherapy…) are eligible.

        Exclusion Criteria:

          -  Patients who have received targeted treatment at the target location either in the
             form of radiotherapy, surgery or interventional radiology (cementoplasty, cryotherapy,
             radiofrequency).

          -  Fractured pathological target bone.

          -  Patients under trusteeship.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cyrille CONFAVREUX, PR</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service de Rhumatologie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cyrille CONFAVREUX, PR</last_name>
    <phone>4.78.86.12.31</phone>
    <phone_ext>+33</phone_ext>
    <email>cyrille.confavreux@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sara CALATTINI</last_name>
    <phone>4.78.86.37.79</phone>
    <phone_ext>+33</phone_ext>
    <email>sara.calattini@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de rhumatologie, CHU d'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Béatrice BOUVARD</last_name>
      <phone>2 41 35 35 76</phone>
      <phone_ext>+33</phone_ext>
      <email>bebouvard@chu-angers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de radiothérapie, Institut Jean-Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurélie BELLIERE</last_name>
      <phone>4 73 27 81 42</phone>
      <phone_ext>+33</phone_ext>
      <email>aurelie.belliere@laposte.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de rhumatologie, CH Annemasse</name>
      <address>
        <city>Contamine-sur-Arve</city>
        <zip>74130</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnaud MAZOUYES</last_name>
      <phone>4 50 82 29 81</phone>
      <phone_ext>+33</phone_ext>
      <email>amazouyes@ch-alpes-léman.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de rhumatologie, CHU de Grenoble</name>
      <address>
        <city>La Tronche</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Athan BAILLET</last_name>
      <phone>4 76 76 70 82</phone>
      <phone_ext>+33</phone_ext>
      <email>abaillet@chu-grenoble.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service d'onco-rhumatologie, Centre Oscar Lombret</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Hélène VIEILLARD</last_name>
      <phone>3 20 44 40 58</phone>
      <phone_ext>+33</phone_ext>
      <email>mh-vieillard@chru-lille.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Radiothérapie, Centre Léon Bérard, 28 Prom. Léa et Napoléon Bullukian</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Line CLAUDE</last_name>
      <phone>4 78 78 26 49</phone>
      <phone_ext>+33</phone_ext>
      <email>line.claude@lyon.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service d'oncologie médicale, Institut Curie, 26 rue d'Ulm</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas GIRARD</last_name>
      <phone>1 56 61 62 50</phone>
      <phone_ext>+33</phone_ext>
      <email>nicolas.girard2@curie.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Radiologie, Hôpital Cochin, Assistance Publique - Hôpitaux de Paris</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine FEYDY</last_name>
      <phone>1 58 41 24 83</phone>
      <phone_ext>+33</phone_ext>
      <email>antoine.feydy@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Rhumatologie, Hospices Civils de Lyon, Groupement Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cyrille CONFAVREUX, PR</last_name>
      <phone>4 78 86 12 31</phone>
      <phone_ext>+33</phone_ext>
      <email>Cyrille.confavreux@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de rhumatologie, CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Françoise DEBIAIS</last_name>
      <phone>5 49 44 44 65</phone>
      <phone_ext>+33</phone_ext>
      <email>francoise.debiais@chu-poitiers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de rhumatologie, CHU de Saint Etienne</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry THOMAS</last_name>
      <phone>4 77 12 76 42</phone>
      <phone_ext>+33</phone_ext>
    </contact>
    <contact_backup>
      <last_name>Karima BOUSSOUALI</last_name>
      <phone>4 77 12 76 42</phone>
      <phone_ext>+33</phone_ext>
      <email>Karima.boussoualim@chu-st-etienne.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 18, 2019</study_first_submitted>
  <study_first_submitted_qc>November 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2019</study_first_posted>
  <last_update_submitted>November 28, 2019</last_update_submitted>
  <last_update_submitted_qc>November 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>osteolytic secondary tumoral lesion</keyword>
  <keyword>femur</keyword>
  <keyword>vertebrae</keyword>
  <keyword>qCT routine imagery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

